<span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">atezolizumab based treatment</span> <span style="margin-left: 3em;">atezolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">atezolizumab plus bevacizumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">avelumab based treatment</span> <span style="margin-left: 3em;">avelumab plus axitinib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">VEGF(R) inhibitor</span> <span style="margin-left: 1em;">sunitinib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
progression or deaths (PFS) (4) objective responses (ORR) (4) deaths (OS) (2) DOR (2) PFS (extension) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 IMmotion-151 (PDL1 >1%), 2019 1 JAVELIN Renal 101( PDL1>1%), 2019 atezolizumab plus bevacizumab vs. avelumab plus axitinib
1.22 [0.85; 1.74] 1.22 [0.85;1.74]atezolizumab plus bevacizumab vs. avelumab plus axitinib
1.22 [0.85; 1.74] atezolizumab plus bevacizumab vs. sunitinib
0.84 [0.62; 1.14] 0.84 [0.62;1.14]atezolizumab plus bevacizumab vs. sunitinib
0.84 [0.62; 1.14] avelumab plus axitinib vs. atezolizumab plus bevacizumab
0.82 [0.57; 1.18] 0.82 [0.57;1.18]avelumab plus axitinib vs. atezolizumab plus bevacizumab
0.82 [0.57; 1.18] avelumab plus axitinib vs. sunitinib
avelumab plus axitinib better
0.69 [0.58; 0.83] 0.69 [0.58;0.83]avelumab plus axitinib vs. sunitinib
avelumab plus axitinib better
0.69 [0.58; 0.83] sunitinib vs. atezolizumab plus bevacizumab
1.19 [0.87; 1.62] 1.19 [0.87;1.62]sunitinib vs. atezolizumab plus bevacizumab
1.19 [0.87; 1.62] sunitinib vs. avelumab plus axitinib
avelumab plus axitinib better
1.45 [1.21; 1.74] 1.45 [1.21;1.74]sunitinib vs. avelumab plus axitinib
avelumab plus axitinib better
1.45 [1.21; 1.74] sunitinib atezolizumab plus bevacizumab avelumab plus axitinib atezolizumab alone direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C sunitinib atezolizumab plus bevacizumab avelumab plus axitinib atezolizumab alone sunitinib --- 1.19 0.87; 1.621.45 1.21; 1.74NA atezolizumab plus bevacizumab 0.84 0.62; 1.14--- 1.22 0.85; 1.74NA avelumab plus axitinib 0.69 0.58; 0.830.82 0.57; 1.18--- NA atezolizumab alone NA NA NA ---
pathologies: 152
- treatments: 361
result logic